Clinical Trials

100 enrolled

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

70 enrolled

Phase 2 Not yet recruiting

Advanced Lung Neuroendocrine Tumor

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

NCT04485559 2026-03-16

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Phase 1 Recruiting

50 enrolled

Glioma

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Neoplasm Metastasis

NCT05918302 2026-03-06

LEVEL

120 enrolled

Thymus Neoplasms, Neuroendocrine Tumors

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05843253 2026-03-04

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

120 enrolled

CNSEndocrineGenitourinary

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

40 enrolled

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT06943755 2026-02-27

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Phase 1/2 Not yet recruiting

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07435584 2026-02-27

EVER-RECODE

38 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Phase 4 Not yet recruiting

Carcinoma, Renal Cell

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT06955169 2026-02-17

MOMENTUM-1

153 enrolled

Meningioma

NCT02397083 2026-02-13

LEVER

102 enrolled

Endometrial Hyperplasia

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms, Recurrence

NCT07405164 2026-02-12

MK-6482-043

450 enrolled

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07407517 2026-02-12

POLARIS

904 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Endometrial Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Phase 2 Not yet recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT07340541 2026-02-09

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT05476939 2026-02-05

BIOMEDE 2

433 enrolled

Diffuse Intrinsic Pontine Glioma

NCT02962414 2026-02-03

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase 4 Active not recruiting

206 enrolled

Seizures, Tuberous Sclerosis

NCT05252585 2026-02-03

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

4 enrolled

Tuberous Sclerosis, Angiomyolipoma

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

EndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT05477576 2026-01-20

ACTION-1

EndocrineGastrointestinalNET

288 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05933395 2026-01-20

GERTRUDE

135 enrolled

Neoplasm Metastasis

NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

249 enrolled

Advanced Cancer

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled

Neoplasm Metastasis

NCT03950609 2026-01-09

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms

NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

31 enrolled

Phase IB

NCT06428396 2025-12-26

LITESPARK-029

120 enrolled

Breast Neoplasms

NCT00799188 2025-12-19

CERTICOEUR

Phase 3 Completed

175 enrolled

Dermatologic

Skin Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

LymphoidOther hematologic neoplasm

45 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT01797523 2025-11-06

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

62 enrolled

Endometrial Neoplasms

NCT01582191 2025-10-27

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

151 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Other solid neoplasmSarcoma

610 enrolled

Advanced Solid Tumors

NCT07218575 2025-10-20

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Phase 2/3 Not yet recruiting

60 enrolled

Autistic Disorder, Hamartoma Syndrome, Multiple

NCT05501769 2025-09-26

TACTIVE-E

Phase 1 Completed

32 enrolled

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

460 enrolled

Breast Neoplasms

NCT01120249 2025-09-16

S0931

Phase 3 Completed

1,545 enrolled 15 charts